Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis

Surgery (United States)

Volumn 158, Issue 6, 2015, Pages 1704-1713

  Chen, Han ^a   Peng, Huan ^b   Liu, Wenwu ^c   Sun, Yanping ^d   Su, Ning ^d   Tang, Wentao ^b   Zhang, Xiaoli ^a   Wang, Jian ^d   Cui, Long ^b   Hu, Pingfang ^d   Liu, Sheng ^a  

^a No 411 Hospital of PLA   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; AGED; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IN VITRO STUDY; INCIDENCE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE; XENOGRAFT;

AGED; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HETEROGRAFTS; HUMANS; IN VITRO TECHNIQUES; INCIDENCE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 84947019608     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.04.053     Document Type: Article

References (33)

1. World Health Organization Cancer incidence in five continents 2002 The World Health Organization and The International Agency for Research on Cancer Lyon
2. World Cancer Research Fund and American Institute for Cancer Research Food, nutrition, physical activity, and the prevention of cancer: a global perspective 2007 American Institute for Cancer Research Washington, DC
3. P. Boyle, and J.S. Langman ABC of colorectal cancer: Epidemiology BMJ 321 2000 805 808
4. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
5. K.R. Sheth, and B.M. Clary Management of hepatic metastases from colorectal cancer Clin Colon Rectal Surg 18 2005 215 223
6. P.A. Andreasen PAI-1- A potential therapeutic target in cancer Curr Drug Targets 8 2007 1030 1041
7. S. Stefansson, G.A. McMahon, E. Petitclerc, and D.A. Lawrence Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling Curr Pharm Des 9 2003 1545 1564
8. E. Angenete, M. Langenskiöld, I. Palmgren, P. Falk, T. Oresland, and M.L. Ivarsson uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome J Surg Res 153 2009 46 53
9. M. Langenskiöld, L. Holmdahl, E. Angenete, P. Falk, S. Nordgren, and M.L. Ivarsson Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer Tumour Biol 30 2009 210 220
10. N.B. Liabakk, I. Talbot, R.A. Smith, K. Wilkinson, and F. Balkwill Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer Cancer Res 56 1996 190 196
11. S. Curran, and G.I. Murray Matrix metalloproteinases in tumour invasion and metastasis J Pathol 189 1999 300 308
12. W. Remmele, and H.E. Stegner Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 1987 138 140
13. W. Tang, Y. Zhu, J. Gao, J. Fu, C. Liu, Y. Liu, and et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4 Br J Cancer 110 2014 450 458
14. C.F. Sier, H.J. Vloedgraven, S. Ganesh, G. Griffioen, P.H. Quax, J.H. Verheijen, and et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis Gastroenterology 107 1994 1449 1456
15. L. Tang, and X. Han The urokinase plasminogen activator system in breast cancer invasion and metastasis Biomed Pharmacother 67 2013 179 182
16. Y. Wei, M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosenberg, M.V. Doyle, and et al. Regulation of integrin function by the urokinase receptor Science 273 1996 1551 1555
17. S. Stefansson, and D. Lawrence The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin Nature 383 1996 441 443
18. G. Deng, S.A. Curriden, S. Wang, S. Rosenberg, and D.J. Loskutoff Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134 1996 1563 1571
19. J. Abe, T. Urano, H. Konno, Y. Erhan, T. Tanaka, N. Nishino, and et al. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size Cancer 86 1999 2602 2611
20. S.M. Kanse, C. Kost, O.G. Wilhelm, P.A. Andreasen, and K.T. Preissner The urokinase receptor is a major vitronectin-binding protein on endothelial cells Exp Cell Res 224 1996 344 353
21. K. Bajou, A. Noël, R.D. Gerard, V. Masson, N. Brunner, C. Holst-Hansen, and et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization Nat Med 4 1998 923 928
22. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
23. L.V. Beerepoot, E.O. Witteveen, G. Groenewegen, W.E. Fogler, B.K. Sim, C. Sidor, and et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study Clin Cancer Res 9 2003 4025 4033
24. P. Vihinen, and V.M. Kähäri Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets Int J Cancer 99 2002 157 166
25. H. Sato, T. Takino, and H. Miyamori Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis Cancer Sci 96 2005 212 217
26. M. Johnsen, L.R. Lund, J. Rømer, K. Almholt, and K. Danø Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation Curr Opin Cell Biol 10 1998 667 671
27. Z.S. Zeng, Y. Huang, A.M. Cohen, and J.G. Guillem Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9 J Clin Oncol 14 1996 3133 3140
28. B.B. Aggarwal, S. Shishodia, S.K. Sandur, M.K. Pandey, and G. Sethi Inflammation and cancer: how hot is the link? Biochem Pharmacol 72 2006 1605 1621
29. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
30. D. Wang, and R.N. Dubois Prostaglandins and cancer Gut 55 2006 115 122
31. C. Kluft, J.H. Verheijen, A.F. Jie, D.C. Rijken, F.E. Preston, H.M. Sue-Ling, and et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma Scand J Clin Lab Invest 45 1985 605 610
32. W.P. Fay Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury Trends Cardiovasc Med 14 2004 196 202
33. G.V. Halade, Y.F. Jin, and M.L. Lindsey Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation Pharmacol Ther 139 2013 32 40